Cargando…
ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes
BACKGROUND: In case of high grade non-muscle invasive bladder cancer (HG-NMIBC), intravesical BCG represents the first-line treatment; despite the “gold” standard therapy, up to 50% of patients relapse, needing radical cystectomy. Hence, alternative therapeutic strategies have been developed. The ai...
Autores principales: | Racioppi, Marco, Di Gianfrancesco, Luca, Ragonese, Mauro, Palermo, Giuseppe, Sacco, Emilio, Bassi, Pier Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282335/ https://www.ncbi.nlm.nih.gov/pubmed/30522445 http://dx.doi.org/10.1186/s12885-018-5134-7 |
Ejemplares similares
-
Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer?
por: Racioppi, Marco, et al.
Publicado: (2019) -
Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle?
por: Busetto, Gian Maria, et al.
Publicado: (2023) -
Investigation of the mechanisms of action behind Electromotive Drug Administration (EMDA)
por: Kos, Bor, et al.
Publicado: (2016) -
The indispensable role of urinalysis for patients undergoing treatment for nonmuscle invasive bladder cancer
por: Di Gianfrancesco, Luca, et al.
Publicado: (2022) -
Office bladder distention with Electromotive Drug Administration (EMDA) is equivalent to distention under General Anesthesia (GA)
por: Rose, Amy E, et al.
Publicado: (2005)